AXIM Biotechnologies (AXIM) 10-Q/A 2 Jul 20 2020 Q1 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - $ / shares	Jun. 29, 2020	Mar. 31, 2020
Details
Registrant CIK		0001514946
Fiscal Year End		--12-31
Document Type		10-Q/A
Document Quarterly Report		true
Document Period End Date		Mar. 31, 2020
Document Transition Report		false
Entity File Number		000-54296
Entity Registrant Name		AXIM Biotechnologies, Inc.
Entity Incorporation, State or Country Code		NV
Entity Tax Identification Number		27-4029386
Entity Address, Address Line One		6191 Cornerstone Court
Entity Address, Address Line Two		E. Suite 114
Entity Address, City or Town		San Diego
Entity Address, State or Province		CA
Entity Address, Postal Zip Code		92121
Entity Address, Address Description		Address of principal executive offices
City Area Code		858
Local Phone Number		923-4422
Phone Fax Number Description		Registrant’s telephone number, including area code
Entity Current Reporting Status		Yes
Entity Interactive Data Current		No
Entity Filer Category		Non-accelerated Filer
Entity Small Business		true
Entity Emerging Growth Company		false
Entity Shell Company		false
Entity Common Stock, Shares Outstanding	131,089,578
Entity Listing, Par Value Per Share	$ 0.0001
Amendment Flag		false
Document Fiscal Year Focus		2020
Document Fiscal Period Focus		Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets, (March 31, 2020, Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 442,749	$ 511,630
Accounts receivable	175	315,843
Inventory	510,301	487,814
Prepaid expenses	43,634	77,606
Loan receivable	5,000	5,000
Marketable securities	109,040	213,745
Investment in Joint Venture	27,490	27,490
Total current assets	1,138,389	1,639,128
Property, Plant and Equipment, Net	25,273	2,237
Other Assets:
Acquired intangible asset - intellectual property licensing agreement, net	47,375	50,534
Patent - Sapphire	249,521	0
Goodwill	3,541,451	0
Research in progress	5,900,000	0
Security deposit	12,785	0
Total other assets	9,751,132	50,534
TOTAL ASSETS	10,914,794	1,691,899
Current liabilities:
Accounts payable and accrued liabilities	939,625	774,781
Due to Cross & Company	518,948	0
Due to shareholder	5,000	5,000
Due to first insurance funding	7,782	42,121
Due to related party	1,526,603	1,526,603
Promissory note (related party note payable $1,053,436, including $173,436 interest)	1,382,571	1,046,926
Total current liabilities	4,380,529	3,395,431
Long-term liabilities:
Deferred tax liability	1,845,000	0
Convertible note payable net of unamortized debt discount	5,050,977	5,056,865
Total long-term liabilities	6,895,977	5,056,865
TOTAL LIABILITIES	11,276,506	8,452,296
STOCKHOLDERS' DEFICIT
Common Stock, Value, Issued	12,331	6,485
Additional paid in capital	37,094,266	28,623,060
Common stock, to be issued	0	50,000
Accumulated deficit	(37,468,409)	(35,440,042)
TOTAL STOCKHOLDERS' DEFICIT	(361,712)	(6,760,397)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	10,914,794	1,691,899
Series B Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred Stock, Value, Issued	50	50
Series C Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred Stock, Value, Issued	$ 50	$ 50

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets, (March 31, 2020, Unaudited) - Parenthetical - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	123,309,045	64,854,539
Common Stock, Shares, Outstanding	123,309,045	64,854,539
Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Series B Convertible Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000
Series C Convertible Preferred Stock
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000
Promissory note - related party
Interest Payable, Current	$ 173,436

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Revenues	$ 7,140	$ 17,061
Cost of goods sold	2,417	4,381
Gross profit	4,723	12,680
Operating Expenses:
Research and development expenses	620,510	532,679
Selling, general and administrative	1,231,046	1,772,831
Depreciation	839	839
Total operating expenses	1,852,395	2,306,349
Loss from operations	(1,847,672)	(2,293,669)
Other (income) expenses:
Unrealized loss on marketable securities	104,705	(25,000)
Amortization	19,363	18,662
Interest expense	56,627	55,346
Total other (income) expenses	180,695	49,008
Loss before provision of income tax	(2,028,367)	(2,342,677)
Provision for income tax	0	0
Net Income (Loss) Attributable to Parent	(2,028,367)	(2,342,677)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (2,028,367)	$ (2,342,677)
Loss per common share - basic and diluted	$ (0.03)	$ (0.04)
Weighted average common shares outstanding - basic and diluted	75,052,908	60,252,001

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Preferred Stock	Series A Convertible Preferred stock	Series B Convertible Preferred Stock	Series C Convertible Preferred Stock	Issued	Additional Paid-in Capital	Retained Earnings	Total
Equity Balance, Starting at Dec. 31, 2018	$ 5,958	$ 0	$ 0	$ 50	$ 50	$ 41,000	$ 22,863,608	$ (28,992,485)	$ (6,081,819)
Shares Outstanding, Starting at Dec. 31, 2018	59,582,890	0	0	500,000	500,000
Stock Issued During Period, Value, New Issues	$ 0	$ 0	$ 0	$ 0	$ 0	7,500	0	0	7,500
Stock Issued During Period, Shares, New Issues	0	0	0	0	0
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition	$ 0	$ 0	$ 0	$ 0	$ 0	0	1,137,500	0	1,137,500
Stock Issued During Period, Value, Other	$ 125	$ 0	$ 0	$ 0	$ 0	0	1,592,687	0	1,592,812
Stock Issued During Period, Shares, Other	1,250,000	0	0	0	0
Stock Issued During Period, Value, Acquisitions	$ 24	$ 0	$ 0	$ 0	$ 0	0	399,976	0	400,000
Stock Issued During Period, Shares, Acquisitions	239,521	0	0	0	0
Net Income (Loss)	$ 0	$ 0	$ 0	$ 0	$ 0	0	0	(2,342,677)	(2,342,677)
Shares Outstanding, Ending at Mar. 31, 2019	61,072,411	0	0	500,000	500,000
Equity Balance, Ending at Mar. 31, 2019	$ 6,107	$ 0	$ 0	$ 50	$ 50	48,500	25,993,771	(31,335,162)	(5,286,684)
Equity Balance, Starting at Dec. 31, 2019	$ 6,485	$ 0	$ 0	$ 50	$ 50	50,000	28,623,060	(35,440,042)	(6,760,397)
Shares Outstanding, Starting at Dec. 31, 2019	64,854,539	0	0	500,000	500,000
Stock Issued During Period, Value, New Issues	$ 25	$ 0	$ 0	$ 0	$ 0	(50,000)	49,975	0	0
Stock Issued During Period, Shares, New Issues	250,000	0	0	0	0
Stock Issued During Period, Value, Other	$ 355	$ 0	$ 0	$ 0	$ 0	0	962,145	0	962,500
Stock Issued During Period, Shares, Other	3,541,667	0	0	0	0
Stock Issued During Period, Value, Acquisitions	$ 5,400	$ 0	$ 0	$ 0	$ 0	0	7,500,600	0	7,506,000
Stock Issued During Period, Shares, Acquisitions	54,000,000	0	0	0	0
Stock Issued During Period, Value, Issued for Services	$ 66	$ 0	$ 0	$ 0	$ 0	0	287,434	0	287,500
Stock Issued During Period, Shares, Issued for Services	662,839	0	0	0	0
Subscription price adjustment	$ 0	$ 0	$ 0	$ 0	$ 0	0	(518,948)	0	(518,948)
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 0	$ 0	$ 0	$ 0	$ 0	0	190,000	0	190,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	0	0	0	0	0
Net Income (Loss)	$ 0	$ 0	$ 0	$ 0	$ 0	0	0	(2,028,367)	(2,028,367)
Shares Outstanding, Ending at Mar. 31, 2020	123,309,045	0	0	500,000	500,000
Equity Balance, Ending at Mar. 31, 2020	$ 12,331	$ 0	$ 0	$ 50	$ 50	$ 0	$ 37,094,266	$ (37,468,409)	$ (361,712)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,028,367)	$ (2,342,677)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation	839	839
Stock based compensation	287,500	1,145,000
Amortization of prepaid insurance	31,280	25,768
Amortization of debt discount	19,363	18,662
Amortization of intangible assets	3,637	3,158
Unrealized gain (loss) on marketable securities	104,705	(25,000)
Changes in operating assets & liabilities:
Decrease (increase) in accounts receivable	315,668	(13,000)
Decrease in prepaid expenses	2,692	0
Increase in Inventory	(22,487)	(68,676)
Increase in due to First Insurance Funding	(34,339)	(23,280)
Increase in accounts payable and accrued expenses	211,656	545,705
Decrease in security deposits	0	4,952
Increase in property and equipment	(3,342)	0
Net cash used in operating activities	(1,111,195)	(728,549)
CASH FLOW FROM INVESTING ACTIVITIES:
Cash acquired in acquisition	79,814	0
Net cash provided by investing activities	79,814	0
CASH FLOW FROM FINANCING ACTIVITIES:
Repayment of related party loans	0	(7,500)
Common stock issued under registration statement on Form S-3	962,500	1,592,812
Net cash provided by financing activities	962,500	1,585,312
Net (decrease) increase in cash and cash equivalents	(68,881)	856,763
Cash and cash equivalents at beginning of period	511,630	1,805,627
Cash and cash equivalents at end of period	442,749	2,662,390
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest	0	0
Income taxes - net of tax refund	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued against common stock to be issued	50,000	0
Account receivable against conversion of debt and interest	75,074	0
Common stock issued against CS subscription	0	400,000
Shares issued for acquisition of Sapphire Biotechnology	7,506,000	0
Deferred tax liability accounted for as a result of Sapphire Biotech Acquisition	1,845,000	0
Assets acquired and liability assumed as a result of Sapphire Biotech Acquisition	525,365	0
BCF related to discount on conversion	190,000	0
Other	71,782	0
Subscription price adjustment	$ 518,948	$ 0

NOTE 1_ ORGANIZATION

NOTE 1: ORGANIZATION	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 1: ORGANIZATION	NOTE 1: ORGANIZATION The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company’s principal executive office is located at 45 Rockefeller Plaza 20th Floor, Suite 83, New York, NY 10111. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. On May 11, 2015 the Company acquired a 100% interest in Can Chew License Company a Nevada incorporated licensing Company, through the exchange of 5,826,706 shares of its common stock.

NOTE 2_ ACQUISITION OF SAPPHIRE

NOTE 2: ACQUISITION OF SAPPHIRE BIOTECH, INC.	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 2: ACQUISITION OF SAPPHIRE BIOTECH, INC.	NOTE 2: ACQUISITION OF SAPPHIRE BIOTECH, INC. On March 17, 2020, the Company entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company intends to: (i) acquire 100% of Sapphire’s outstanding capital (consisting of 100,000,000 shares of common stock and zero (0) shares of Preferred Stock); and (ii) assume all of the outstanding debt of Sapphire. The outstanding debt includes two (2) convertible notes in the principal amounts of $310,000 and $190,000, respectfully. Pursuant to the terms of the Share Exchange Agreement, the Company acquired 100% of the issued and outstanding shares of Sapphire by means of a share exchange with the Sapphire Stockholders in exchange for 54,000,000 newly issued shares of the common stock of AXIM (the “Share Exchange”). As a result of the Share Exchange, Sapphire became a 100% owned subsidiary of AXIM, which on a going forward basis will result in consolidated financial reporting by AXIM to include the results of Sapphire. The closing of the Share Exchange occurred concurrently with entry into the Share Exchange Agreement (the “Closing”).

NOTE 3_ BASIS OF PRESENTATION

NOTE 3: BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 3: BASIS OF PRESENTATION:	NOTE 3: BASIS OF PRESENTATION: The unaudited condensed consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) The following (a) balance sheets as of March 31, 2020 (unaudited) and December 31, 2019, which have been derived from audited financial statements, and (b) the unaudited interim statements of operations and cash flows of AXIM Biotechnologies, Inc. (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily indicative of results that may be expected for the year ending December 31, 2020. These unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on May 14, 2020.

NOTE 4_ GOING CONCERN

NOTE 4: GOING CONCERN	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 4: GOING CONCERN	NOTE 4: GOING CONCERN The Company’s condensed consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the condensed consolidated financial statements, the Company has negative working capital of $3,242,140 and has an accumulated deficit of $37,468,409 has cash used in operating activities of continuing operations $1,111,195. The Company extinguished its old debt and entered in debt exchange agreement. On April 16, 2018, the Company entered into a Stock Purchase Agreement and sold 3,945,000 shares of our common stock registered under the Registration Statement on Form S-3 declared effective by the Securities and Exchange Commission on September 14, 2017. This includes sales for the three months ended March 31, 2020, during which the Company sold 3,541,667 shares and raised additional capital of $962,500 through this Stock Purchase Agreements. This capital provides funds for research, development, and ongoing operations. The Company intends to raise substantial additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. That will raise a doubt about the ability of the Company to continue as a going concern. The consolidated

NOTE 5_ SIGNIFICANT ACCOUNTING

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 5: SIGNIFICANT ACCOUNTING POLICIES	NOTE 5: SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate. Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at March 31, 2020 and December 31, 2019. The Company has never experienced any losses related to these balances. Accounts Receivable It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers. Concentrations At March 31, 2020 and December 31, 2019, one customer and two customers accounted for 100% and 100% of accounts receivable, respectively. For the three months period ended March 31, 2020, one customer accounted for 24% of total revenue. For the three months period ended March 31, 2019, one customer accounted for 76% of total revenue. Inventory Inventory consists of finished goods available for sale and raw materials owned by the Company and are stated at the lower of cost or market. As of March 31, 2020 and December 31, 2019, the Company had $218,829 and $175,304 of finished goods and $291,472 and $312,511 of raw materials; respectively. Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. For the three months ended March 31, 2020 and 2019 the Company recorded $839 of depreciation expenses for each of these periods. Intangible Assets As required by generally accepted accounting principles, trademarks and patents are amortized if they have a definite life, and not amortized if they have an indefinite life and then they are tested annually for impairment. Intangible assets as of March 31, 2020 and December 31, 2019 amounted to $9,738,347 and $50,534 net of accumulated amortization and impairment losses of $668,535 and $664,898, respectively. During the three months period ended March 31, 2020 and 2019, the company recorded $3,637 and $3,158 of amortization and impairment loss, respectively. Revenue Recognition On January 1, 2018 the Company adopted guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from operations recognized for three month ended March 31, 2020 and 2019 amounted to $7,140 and $17,061, respectively. Principles of Consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc. Can Chew License Company, Marina Street LLC, Axim Biotechnologies (the Netherland Company) and Sapphire Biotech, Inc. and wholly-owned subsidiary Sapphire Diagnostics LLC as of March 31, 2020. All significant intercompany transactions and balances have been eliminated in consolidation. Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of March 31, 2020 and December 31, 2019, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. Fair Value Measurements The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The provisions of ASC 820-10 only apply to the Company’s investment securities, which are carried at fair value. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment The Company categorizes a financial instrument in the fair value hierarchy based on the lowest level of input that is significant to its fair value measurement. As of March 31, 2020 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair ValueReported inFinancial Statements Marketable Securities $109,040 $ - $ - $109,040 As of December 31, 2019 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair Value Reported in Financial Statements Marketable Securities $213,745 $ - $ - $213,745 The Company recorded a change in FMV of trading securities as unrealized loss of $104,705 and unrealized gain of $25,000 for the three months ended March 31, 2020 and 2019, respectively. These securities are classified as trading. The Company did not have any Level 2 or Level 3 assets or liabilities as of March 31, 2020 and December 31, 2019, except for its convertible notes payable and derivative liability. The carrying amounts of these liabilities at March 31, 2020 and December 31, 2019 approximate their respective fair value based on the Company’s incremental borrowing rate. Cash is as of March 31, 2020 and December 31, 2019 is classified as Level 1 within our fair value hierarchy. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”. Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument”. The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Income Taxes The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. The Company had $240,769 and 0 allowance for doubtful accounts at March 31, 2020 and December 31, 2019. The Company had $175 accounts receivable at March 31, 2020 and $315,843 at December 31, 2019. Net Loss per Common Share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were 22,367,172 common share equivalents at March 31, 2020 and 16,295,498 common shares at December 31, 2019. For the three months ended March 31, 2020 and 2019 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $620,510 and $532,679 for the three months ended March 31, 2020 and 2019 respectively. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Recently Issued Accounting Standards In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements The Company has a long-term operating lease, and the long-term operating lease only took effect in April 2020. Thus the adoption of ASC 842 had no impact on the condensed consolidated financial statements. In November 2018, the FASB issued ASU 2018-18 , Collaborative Arrangements (Topic 818): Clarifying the Interaction Between Topic 808 and Topic 606 In October 2018, the FASB issued ASU 2018-17, Targeted Improvements to Related Party Guidance for Variable Interest Entities In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 6_ PREPAID EXPENSES

NOTE 6: PREPAID EXPENSES	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 6: PREPAID EXPENSES	NOTE 6: PREPAID EXPENSES Prepaid expenses consist of the following as of March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Prepaid insurance $ 36,455 $ 67,734 Prepaid raw material/inventory 7,179 9,872 $ 43,634 $ 77,606 For the three months ended March 31, 2020 and 2019, the Company recognized amortization of prepaid expense of $31,280 and $25,768, respectively.

NOTE 7_ MARKETABLE SECURITIES

NOTE 7: MARKETABLE SECURITIES	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 7: MARKETABLE SECURITIES	NOTE 7: MARKETABLE SECURITIES The Company received marketable securities, 10,300,000 fully paid ordinary unrestricted shares in Impression Healthcare Limited (Australian Company), traded on Australian Security Exchange by the code IHL as part of the agreement and letter of intent (LOI). The Company categorize these securities as trading securities and report them at fair value, with unrealized gains and losses included in earnings. On December 31, 2019, the Company received another 2,000,000 shares and sold 7,375,000 shares. On December 31, 2019 the stock price was A$ 0.062 per share as quoted on asx.com.au and exchange rate of $0.7 AUD/USD as quoted on oanda.com and had FMV $213,745. The change to the FMV in marketable security for this period resulted in realized and unrealized gain of $268,274 and $113,748 respectively. As of March 31, 2020 the stock price was A$ 0.036 per share as quoted on asx.com.au and exchange rate of $0.615 AUD/USD as quoted on olanda.com. The Company recorded securities at FMV valued at $109,040. For the three months ended March 31, 2020 and 2019, the Company recorded realized and unrealized gain (loss) of $-0-, $-0-, ($104,705) and $25,000, respectively.

NOTE 8_ INVESTMENT IN THIRD PAR

NOTE 8: INVESTMENT IN THIRD PARTY	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 8: INVESTMENT IN THIRD PARTY	NOTE 8: INVESTMENT IN THIRD PARTY On June 11, 2019 the Company entered in operating agreement as 1/3 member of KAM Industries, LLC, a Wyoming Limited Company. On June 18, 2019 KAM Industries LLC, entered into Joint Venture Agreement to receive a percentage of the industrial hemp harvest yield on a parcel of land in Wayne County, North Carolina owned by Farm Share, LLC with whom KAM contracted to purchase a percentage of the hemp harvest for the 2019 growing season. Once the hemp is harvested from the 2019 growing season The Company will get its 1/3 share at no additional cost. The agreement then expires unless renewed for 2020 with an additional payment. The Company paid $27,490 for 33.3% of KAM Industries, LLC and recorded $27,490 as current asset as of December 31, 2019. This investment is counted by using cost method of accounting. An officer in KAM Industries, LLC is the Company’s CEO. As of March 31, 2020, Farm Share, LLC is in the middle of the processing of the entire 2019 crop. During the virus shut down the extraction laboratories were not considered essential, but they were back in business as of June 11, 2020.

NOTE 9_ PROMISSORY NOTE - RELAT

NOTE 9: PROMISSORY NOTE - RELATED PARTY	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 9: PROMISSORY NOTE - RELATED PARTY	NOTE 9: PROMISSORY NOTE - RELATED PARTY On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of CCB also own a majority of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The original loan was a demand note bearing interest at the rate of 7% per annum, which amount, along with principal, was payable upon demand. The demand note was amended effective January 1, 2015 to reduce the annual interest rate to 3%. All other terms and conditions shall remain in full force and effect. The Company is in discussions to have the demand note modified or exchanged for a longer term, fixed maturity note. The following table summarizes promissory note payable as of March 31, 2020 and December 31, 2019: March 31, 2020 December31, 2019 Promissory note payable, due on demand, interest at 3% p.a. $ 880,000 $ 880,000 Accrued Interest 173,436 166,926 $ 1,053,436 $ 1,046,926 For the three months ended March 31, 2020 and 2019 the Company recognized interest expense of $6,510 and $6,510, respectively on this note.

NOTE 10_ RELATED PARTY TRANSACT

NOTE 10: RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 10: RELATED PARTY TRANSACTIONS	NOTE 10: RELATED PARTY TRANSACTIONS The Company has received working capital advances from CanChew totaling $1,526,603 and $1,526,603 as of March 31, 2020 and December 31, 2019 respectively. The advances are payable on demand. The Company is in discussions to have the advances reduced to a longer term, fixed maturity note. The Company owes $5,000 to the chairman of the board of the Company for a working capital advance of $5,000 made in May of 2014. Under an agreement Mr. Changoer received on March 20, 2018 the Company issued 50,000 restrictive shares of its common stock and recorded $235,000 of compensation expenses in the accompanying consolidated financial statements to account for the issuance of the incentive shares. As of March 31, 2020 and December 31, 2019, the total outstanding balance was $20,000 and $23,696 respectively for consulting fees to Mr. Changoer. On September 25, 2018, the Company amended Independent Director Compensation agreement. Under the agreement in lieu of the share compensation due to independent director of the Company for his annual service ending May 23, Dr. Philip A. Van Damme shall receive cash compensation of $20,000. Started from August 1, 2019 the company has been paying monthly clinical trial fee of $5,000. As of March 31, 2020 and December 31, 2019, the total outstanding balance was $21,877 and $9,377 respectively. Effective January 1, 2019 the company entered into a thirty-months consulting agreement with the chairman of the board which pays a monthly consulting fee of $20,000. The company has also been paying a monthly bonus fee of 15,000; this additional fee is on a month to month basis at the discretion of management. As of March 31, 2020 and December 31, 2019, the total outstanding balance was $35,000 and $35,000 respectively for consulting fees.

NOTE 11_ DUE TO FIRST INSURANCE

NOTE 11: DUE TO FIRST INSURANCE FUNDING	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 11: DUE TO FIRST INSURANCE FUNDING	NOTE 11: DUE TO FIRST INSURANCE FUNDING On June 25, 2019, the Company renewed its D&O and EPLI insurance policy with total premiums, taxes and fees for $97,000 and $6,849 respectively. A cash down payment of $20,850 was paid on July 16, 2019. Under the terms of the insurance financing, payments of $9,501, which include interest at the rate of 7.2% per annum, are due each month for nine months commencing on July 25, 2019. On October 22, 2019, the Company renewed its CL Products Liability insurance policy with total premiums, taxes and fees for $18,864. A cash down payment of $1,886 was paid on October 24, 2019. Under the terms of the insurance financing, payment of $1,945, which include interest at the rate of 7.451% per annum, are due each month for nine months commencing on November 22, 2019. The total outstanding due to First Insurance Funding as of March 31, 2020 and December 31, 2019 is $7,782 and $42,121; respectively.

NOTE 12_ CONVERTIBLE NOTES PAYA

NOTE 12: CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 12: CONVERTIBLE NOTES PAYABLE	NOTE 12: CONVERTIBLE NOTES PAYABLE The following table summarizes convertible note payable- shareholder as of March 31, 2020 and December 31, 2019 March 31, 2020 December 31, 2019 Convertible note payable, due on July 1, 2028, interest at 3.5% p.a. $ 45,000 $ 45,000 Accrued interest 5,972 5,578 $ 50,972 $ 50,578 The Convertible Note (“Note”) bears interest at the rate of 3.5% per annum, payable annually beginning on July 1, 2017, and matures on July 1, 2028. The Note is convertible, in whole or in part at any time at the option of the holder, into the Company’s common stock at a conversion price of $0.01, provided however, the holder of the Note is not permitted to convert an amount of the Note that would result in the holder and its affiliates owning more than 4.9% of the Company’s outstanding common stock. The balance on the Note as of March 31, 2020 and December 31, 2019 is $50,972 and $50,578, including interest accrued thereon of $5,972 and $5,578, respectively. The following table summarizes convertible note payable as of March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 1,000,000 1,000,000 Convertible note payable, due on November 1, 2021, interest at 3.5% p.a. 4,000,000 4,000,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 - Accrued interest 235,897 261,541 Total 5,910,375 5,746,019 Less: unamortized debt discount/finance premium costs (910,370) (739,732) Convertible note payable, net 5,000,005 5,006,287 Less: current portion - - Long term portion $ 5,000,005 $ 5,006,287 On September 16, 2016, we entered into a convertible note purchase agreement (the “Convertible Note Purchase Agreement” or “Agreement”) with a third-party investor. Under the terms of the Convertible Note Purchase Agreement the investor may acquire up to $5,000,000 of convertible notes from the Company. With various closings, under terms acceptable to the Company and the investor as of the time of each closing. Pursuant to the Agreement, on September 16, 2016 the investor provided the Company with $850,000 secured convertible note financing pursuant to four (4) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes matures on October 1, 2029, and pay 3.5% compounded interest paid bi-annually. The Note are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company common stock at a conversion price equal to (i) $0.2201 or (ii) 80% of closing price of the Company’s common stock as of the date of conversion. At the inception of the Convertible Promissory Note, the Company determined a fair value of $1,062,500 of the embedded derivative. On October 20, 2016, the terms of a above Convertible note was modified into convertible note with fixed conversion price of $0.2201. The derivative liability balance on the Note as of modified date is $1,274,422 re-classed into additional paid in capital. On March 8, 2018, the holder converted $210,422 note, which included $10,422 interest into 956,030 restricted shares of the Company’s common stock. On March 13, 2018 the holder converted $176,080 of convertible note, which included $10,558 interest, into 800,000 shares of the Company’s common stock. As of March 31, 2020 and December 31, 2019, the balance of secured convertible notes was $543,467 and $539,227, which included $58,989 and $54,749 accrued interest, respectively. On October 20, 2016 a third-party investor provided the Company with $1,000,000 secured convertible note financing pursuant to three (3) Secured Convertible Promissory Notes (the “Notes”). Each of the Notes mature on October 1, 2029 and pay 3.5% compounded interest paid bi-annually. The Notes are secured by the assets of the Company, may not be pre-paid without the consent of the holder, and are convertible at the option of the holder into shares of the Company’s common stock at a fixed conversion price equal to (i) $0.2201 or (ii) 80% of closing price of the Company’s common stock as of the date of conversion. The investor paid cash of $500,000 for one of the Notes and issued to the Company two (2) secured promissory notes of $250,000 each for two (2) Convertible Notes of $250,000 each. The two secured promissory notes issued by the investor (totaling $500,000) as payment for two (2) secured Notes totaling $500,000 mature on February 1, 2017 ($250,000) and March 1, 2017 ($250,000), bear interest at the rate of 1% per annum, are full recourse and additionally secured by 10,486,303 shares of Medical Marijuana, Inc. (Pink Sheets symbol: MJNA) and were valued at $858,828 based upon the closing price of MJNA on October 20, 2016. On October 20, 2016, the terms of a above Convertible note was modified into convertible note with fixed conversion price of $0.2201. Since the modification happened on the same day, the note was treated to have fixed conversion price and accordingly debt discount was recorded related to beneficial conversion feature. In connection with this convertible note, the Company recorded a $499,318 discount on debt, related to the beneficial conversion feature of the note to be amortized over the life of the note or until the note is converted or repaid. As of March 31, 2020 and December 31, 2019, this note has not been converted and the balance of secured convertible notes was $1,122,208 and $1,113,458, which included $122,208 and $113,458 accrued interest, respectively. In 2018 the Company extinguished debt with Investor. Investor had proposed a financing transaction pursuant to which the Company will satisfy and retire the Original Note and Original Note current balance in simultaneous exchange for and upon delivery by the Company of a (1) new Convertible Promissory Note in the principal amount of $4,000,000 (the “Exchange Note”), and (2) 400,000 shares of the Company’s restricted common stock (the “Origination Shares”). Simultaneously, a third-party Investor and the Company entered in Debt Exchange Agreement with Medical Marijuana Inc. As part of this agreement Investor will exchange and deliver the AXIM note to Medical Marijuana in exchange for a Convertible Promissory note. Axim consented to the transfer and assignment of the Axim Note in exchange for the issuance by the Medical Marijuana of the Exchange Note. The interest on this note is payable bi-annually every May 1 and November 1. On May 1, 2019 the Company paid accrued interest of $60,278. As of March 31, 2020 and December 31, 2019, the balance of secured convertible note was $4,053,259 and $4,093,333 which included $53,259 and $93,333 accrued interest respectively. On December 31, 2019, Sapphire Biotech, Inc. entered into an Convertible Note Purchase Agreement whereas the Company issued a convertible note with a face value of $190,000 with a compounding interest rate of 3% per annum, the interest shall be payable annually beginning on December 31, 2020 until the maturity date of December 31, 2034, at which time all principal and interest accrued thereon shall be due and payable. The Convertible Note is secured by substantially all the Company’s tangible and intangible assets. In addition, the Convertible Note includes various non-financial covenants including the Company may not enter into any agreement, arrangement or understanding of any kind that would result in a transaction, or series of transactions, that would result in the sale of 50% or more of the Company’s capital stock without the prior approval of the holder. Upon issuance, the Convertible Note was convertible into shares of the Company’s common stock at $1.90 per share. At December 31, 2019, the Company determined that the Convertible Note contained a beneficial conversion feature for which a full discount was recorded on the Convertible Note. The fair market value of the Company’s common stock was based upon the estimated per share acquisition price per the pending acquisition of the Company, see Note 8 for additional information. The discount of $190,000 will be amortized using the effective interest method and will be fully amortized by December 31, 2034. On March 17, 2020, Sapphire Biotech, Inc. entered into a Share Exchange Agreement (“Agreement”) with Sapphire Biotech, Inc., a Delaware corporation (“Sapphire”) and all of the Sapphire stockholders (collectively, the “Sapphire Stockholders”). Following the closing of the transaction, Sapphire will become a wholly owned subsidiary of AXIM. Under the terms of the Agreement, the Company intends to assume the convertible notes in the principal amounts of $190,000. After the acquisition, the Convertible Note was able to convert 6,000,000 shares of Axim’s common stock. Upon assumption of the note, the Company recorded a beneficial conversion feature of $190,000. During the three months ended March 31, 2020 and 2019, the Company amortized the debt discount on all the notes of $19,363 and $18,662, respectively, to other expenses. As of March 31, 2020 and December 31, 2019, the balance of secured convertible note was $191,441 and $0 which included $1,441 and $0 accrued interest respectively. As of March 31, 2020 and 2019, unamortized debt discount was $910,370 and $796,341, respectively. On December 31, 2019, the Company entered into a Debt Exchange Agreement whereas the Company assumed three (3) loans totaling $128,375 of Debt owned by Sapphire Diagnostics, LLC which had an interest rate of 6% per annum. In the same Debt Exchange Agreement, the Company assumed four (4) additional loans made to the Company in 2019, which had an interest rate of 6% per annum. All seven (7) loans totaling $310,000, plus the aggregate interest accrued thereon of $14,218 making the face value of the new note $324,218. For the three months ended March 31, 2020, the principal and accrued interest balances were $324,218 and $756, respectively.

NOTE 13_ STOCK INCENTIVE PLAN

NOTE 13: STOCK INCENTIVE PLAN	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 13: STOCK INCENTIVE PLAN	NOTE 13: STOCK INCENTIVE PLAN On May 29, 2015 the Company adopted its 2015 Stock Incentive Plan. Under the Plan the Company may issue up to 10,000,000 S-8 shares to officers, employees, directors or consultants for services rendered to the Company or its affiliates or to incentivize such parties to continue to render services. S-8 shares are registered immediately upon the filing of the Plan and are unrestricted shares that are free-trading upon issuance. There were 9,806,000 shares available for issuance under the Plan as of December 31, 2019. On January 2, 2019, John Huemoeller the CEO was granted the option to purchase 2 million shares of Axim Common stock under the plan at a purchase price of $0.75 per share. 1 million options vested immediately and 1 million options vest at the end of 2019. For the three months ended March 31, 2020 and 2019 the Company recorded compensation expense of $287,500 and $1,145,000, respectively. As of March 31, 2020, John Huemoeller the CEO hasn’t exercised the option.

NOTE 14_ STOCKHOLDERS' DEFICIT

NOTE 14: STOCKHOLDERS' DEFICIT	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 14: STOCKHOLDERS' DEFICIT	NOTE 14: STOCKHOLDERS’ DEFICIT Preferred Stock The Company has authorized 5,000,000 shares of preferred stock, with a par value of $0.0001 per share. Of the 5,000,000 authorized preferred shares, 4,000,000 are undesignated “blank check” preferred stock. The Company may issue such preferred shares and designate the rights, privileges and preferences of such shares at the time of designation and issuance. As of March 31, 2020, and December 31, 2019 there are -0- and -0- shares of undesignated preferred shares issued and outstanding, respectively. Series A Convertible Preferred Stock The Company also has authorized 1,000,000 shares of Series A Convertible Preferred Stock, which had been previously issued to Sanammad Foundation and subsequently assigned and transferred by Sanammad to Treo Holdings, LLC (“Treo”). On June 28, 2016 the Company, Sanammad and Treo agreed that the issuance of the Series A Convertible Preferred be rescinded and that such share issuance be cancelled. The Company accounted for this cancelation of preferred stock as equity transaction and accordingly the par value of preferred stock adjusted against additional paid in capital account. Each share of the Series A Convertible Preferred Stock is convertible into five (5) shares of the Company’s common stock at any time at the discretion of the holder. The Series A Convertible Preferred Stock provides for a liquidation preference as follows; In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary (a “Liquidation”), the assets of the Company available for distribution to its shareholders shall be distributed as follows. The holders of the Series A Convertible Preferred Stock shall be entitled to receive, prior to the holders of the other series of preferred stock, if any, and prior and in preference to any distribution of the assets or surplus funds of the Company to the holders of any other shares of stock of the Company by reason of their ownership of such stock: (i) all shares of common stock of any subsidiary of the Company which are held by the Company: and (ii) an amount equal to $1.00 per share with respect to each share of Series A Convertible Preferred stock, plus all declared but unpaid dividends with respect to such share. The Series A Convertible Preferred Stock also contains super-majority voting rights and a number of protective covenants. As of March 31, 2020, and December 31, 2019 there are -0- and -0- Series A Convertible Preferred shares issued and outstanding; respectively. Series B Convertible Preferred Stock On August 17, 2016 the Company designated up to 500,000 shares of a new Series B Convertible Preferred Stock (Series B Preferred Stock). The holders of the Series B Preferred are entitled to elect three members to the Company’s board of directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. Each share of Series B Convertible Preferred is convertible into one share of the Company’s common stock. The Series B Convertible Preferred designation contains a number of protective and restrictive covenants that restrict the Company from taking a number of actions without the prior approval of the holders of the Series B Preferred or the unanimous vote of all three Series B Directors. On August 18, 2016 the Company issued all 500,000 shares of its newly designated Series B Preferred Stock to Sanammad Foundation in exchange for cash of $50,000. As the holders of the Series B Preferred Stock, Sanammad has designated the current directors, Dr. George E. Anastassov, Dr. Phillip A. Van Damme and Mr. Lekhram Changoer as their three Series B Directors. Series C Convertible Preferred Stock On August 17, 2016 the Company designated up to 500,000 shares of a new Series C Convertible Preferred Stock (Series C Preferred Stock). The holders of the Series C Preferred are entitled to elect four members to the Company’s board of directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. Each share of Series C Convertible Preferred is convertible into one share of the Company’s common stock. The Series C Convertible Preferred designation contains a number of protective and restrictive covenants that restrict the Company from taking a number of actions without the prior approval of the holders of the Series C Preferred or the unanimous vote of all four Series C Directors. If at any time there are four Series C Directors, one such director must be independent as that term is defined in the Series C designation. Any challenge to the independence of a Series C Director is a right conferred only upon the holders of the Series B Convertible Preferred Stock and may only be made by the holders of the Series B Convertible Preferred Stock. On August 18, 2016 the Company issued all 500,000 shares of its newly designated Series C Preferred Stock to MJNA Investment Holdings, LLC in exchange for cash of $65,000. As the holders of the Series C Preferred Stock, MJNA Investment Holdings, LLC has designated Dr. Timothy R. Scott, John W. Huemoeller II, Robert Cunningham and Blake Schroeder as their four Series C Directors. On February 20, 2019, MJNA Investment Holdings LLC (“Seller”) sold its 500,000 shares of AXIM Biotechnologies, Inc.’s, a Nevada corporation (the “Company”) Series C Preferred Stock to Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”) for a purchase price of $500,000 (the “Purchase Price”) pursuant to a Preferred Stock Purchase Agreement (the “Purchase Agreement”). Payment of the Purchase Price was made as follows (i) a $65,000 payment made by check payable to Seller, which Purchaser borrowed from an unrelated third-party and which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Loan”), and (ii) the issuance by Purchaser to Seller of a promissory note, face value, $435,000, which has no recourse against the Series C Preferred Stock or assets of Purchaser (the “Note”). The Company’s Chief Executive Officer John W. Huemoeller II is the President of Purchaser. Mr. Huemoeller provided a personal guaranty for the Loan and the Note. The holders of the Series C Preferred Stock are entitled to elect four members to the Company’s Board of Directors and are entitled to cast 100 votes per share on all other matters presented to the shareholders for a vote. As a result of this transaction, a change in control has occurred. Effective April 2, 2019, Blake N. Schroeder resigned as a member of the Company’s Board of Directors. Mr. Schroeder’s resignation was not because of any disagreements with the Company on matters relating to its operations, policies and practices. On April 3, 2019 pursuant to the Company’s Amended and Restated Bylaws, the holder of the Company’s Series C Preferred Stock appointed Mauricio Javier Gatto-Bellora to fill the director seat vacated by the resignation of Mr. Schroeder. Common Stock The Company has authorized 300,000,000 shares of common stock, with a par value of $0.0001 per share. As of March 31, 2020, and December 31, 2019, the Company had 123,309,045 and 64,854,539 shares of common stock issued and outstanding, respectively. 2020 Transactions: During the period between January 1, 2020 and March 31, 2020 the Company issued total 3,541,667 shares valued $962,500 pursuant to the Company’s Registration Statement on Form S-3. The Company received $962,500 in cash. The Company has an outstanding subscription price adjustment of $518,948 related to the issuance of the S-3 shares, which it expects to satisfy with the issuance of additional shares. On January 13, 2020 the Company issued 250,000 restricted shares of its common stock to third party valued at $50,000, which were carried on the books as stock to be issued. On January 23, 2020 and February 26, 2020 the Company issued 600,000, and 62,839 restricted shares of its common stock to third party valued at $262,500, and $25,000 pursuant to the stock purchase agreement for certain services, recorded as advertising and promotion expense and License, permits & Patents, respectively. On March 17, 2020 the company acquired 100% of the issued and outstanding shares of Sapphire by means of a share exchange with the Sapphire Stockholders in exchange for 54,000,000 restricted shares of its common stock. 2019 Transactions : During the period between January 1, 2019 and March 31, 2019 the Company issued total 1,250,000 shares valued $1,592,813 pursuant to the Company’s Registration Statement on Form S-3. The Company received $1,592,813 in cash. On March 12, 2019 the Company issued 239,521 restricted shares of its common stock to third party valued at $400,000 pursuant to the stock purchase agreement. The cash was received in 2018.

NOTE 15_ STOCK OPTIONS

NOTE 15: STOCK OPTIONS	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 15: STOCK OPTIONS	NOTE 15: STOCK OPTIONS On January 02, 2019, the Company granted 2,000,000 options with an exercise price of $0.75 per share to the Company owned by Mr. John Huemoeller, Chief Executive Officer of the Company. The following table summarizes the changes in options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at March 31, 2020: Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $0.75 2,000,000 9 $0.75 2,000,000 $0.75 The stock option activity for the year ended March 31, 2020 is as follows: Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2019 2,000,000 $0.75 Granted - - Exercised - - Expired or canceled - - Outstanding at March 31, 2020 2,000,000 $ 0.75 For the three months ended March 31, 2020 and 2019 stock-based compensation expense related to vested options was $0 and $1,137,500, respectively. The Company determined the value of share-based compensation for options vesting during 2019 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.91, risk-free interest rate of 2.66%, volatility of 318%, expected lives of 10 years, and dividend yield of 0%.

NOTE 16_ BUSINESS COMBINATION -

NOTE 16: BUSINESS COMBINATION - SAPPHIRE	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 16: BUSINESS COMBINATION - SAPPHIRE	NOTE 16: BUSINESS COMBINATION – SAPPHIRE In March 2020, the Company acquired SAPPHIRE BIOTECH, Inc., a biotechnology company focusing on improving cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis. The Company issued 54,000,000 shares of common stock with a total fair value of $7,506,000, in exchange for all outstanding shares of SAPPHIRE BIOTECH, Inc. The Company accounted for the acquisition using the purchase method of accounting for business combinations. The purchase price and costs associated with the acquisition exceeded the preliminary estimated fair value of net assets acquired by $9,573,233, which was preliminarily assigned to intangible asset and goodwill. The Company incurred $6,000 of acquisition-related costs, which will be recorded as expense after the evaluation work been completed. The Company expects to complete the valuation of the intangible assets acquired in the SAPPHIRE BIOTECH, Inc. transaction by July 2020. Pursuant to the valuation, the Company may assign a portion of the purchase price to in-process technology that previously had been initially assigned to goodwill. In management’s judgment, the amount assigned to in process research and development would reflect the amount the Company would reasonably expect to pay an unrelated party for each project included in the technology. Based on the final valuation, the remaining excess purchase price will be allocated existing patents and goodwill. The aggregate purchase price of $7,506,000 consisted of common stock valued at $7,506,000. The value of the $7,506,000 common shares issued was determined based on the closing price of the Company’s common shares at the acquisition date. The following table summarizes the consideration paid for SAPPHIRE BIOTECH and the estimated amounts of the assets acquired and liabilities assumed recognized at the acquisition date. Consideration: Cash and cash equivalents $ 79,814 Property and equipment, net 20,533 Intangible assets including goodwill 9,763,233 Security deposit 12,785 Total asset acquired $ 9,876,365 Accrued expenses and other current liabilities $ 5,767 Deferred taxes liability 1,845,000 Notes Payable including convertible and discount on conversion 519,598 Total liabilities assumed $ 2,370,365 Net assets acquired $ 7,506,000 Of the $9,763,233 of acquired intangible assets, $5,900,000 was assigned to in-process research and development and $3,613,233 to goodwill that are not subject to amortization, and $1,845,000 was assigned to deferred tax liability at the date of acquisition. The remaining $250,000 of patent have a weighted-average useful life of approximately 20 years. The $3,613,233 of goodwill is not expected to be deductible for tax purposes. The allocation of the purchase price is based on preliminary data and could change when final valuation of certain intangible assets is obtained. The effective settlement of receivable/payable between the Company and Sapphire was deemed to be not material. Disclosure of Pro Forma Information The following (unaudited) pro forma consolidated results of operations have been prepared as if the acquisition of SAPPHIRE BIOTECH, Inc. had occurred at January 1, 2019: March 31, 2020 March 31, 2019 Revenues $ $7,140 $ $17,061 Net income(loss) $ (2,455,268) $ (2,403,488) Net loss per share—Basic $ (0.02) $ (0.02) Net loss per share—Diluted $ (0.02) $ (0.02) The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisition been consummated as of that time, nor is it intended to be a projection of future results. During the three months ended March 31, 2020 Sapphire had no revenue transactions.

NOTE 17_ COMMITMENT AND CONTING

NOTE 17: COMMITMENT AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 17: COMMITMENT AND CONTINGENCIES	NOTE 17: COMMITMENT AND CONTINGENCIES On September 1, 2016, the Company entered into an amended and restated employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. The agreement does not have a set term and may be terminated at any time by the Company or Dr. Anastassov with proper notice. Under the agreement, Dr. Anastassov receives an annual base compensation of $240,000 and an incentive payment of 2,000,000 shares of the Company’s common stock due upon execution of the agreement. On March 20, 2018 the Company issued 50,000 restrictive shares of its common stock and recorded $235,000 of compensation expenses in the accompanying consolidated financial statements to account for the issuance of the incentive shares. In addition, Dr. Anastassov is currently receiving an additional $15,000 per month as bonus compensation. On January 2, 2019 Dr. George Anastassov resigned as the Chief Executive Officer of Axim Biotechnologies, Inc. Dr. Anastassov will remain a member and Chairman of the Board of Directors and will retain the title of Founder in a consulting role with the Company. On January 2, 2019 the Company entered into the term of Executive’s employment agreement, at a base salary of $10,000 per month with John W. Huemoeller II to serve as its Chief Executive Officer. The Company and Executive acknowledge and agree that Executive’s employment hereunder shall at all times be “at will,” which means that either Executive may resign at any time for any reason or for no reason, and that the Company may terminate Executive’s employment at any time for any reason or for no reason, in either case, subject to the applicable provisions of this Agreement. In further consideration for Executive’s services and subject to the approval of the Board, Executive will be granted an option to purchase 2,000,000 shares of the Company’s common stock (the “Option Shares”). The option will be subject to the terms and conditions applicable to stock options granted under the Company’s 2015 Stock Incentive Plan, as amended from time to time (the “Plan”), and as described in the Plan and the stock option agreement, which Executive will be required to sign. 50% of the Option Shares shall vest on the date of grant and the remaining 50% of the Option Shares shall vest on the 12- month anniversary of the grant date, subject to Executive’s continued employment by the Company. The exercise price per share will be equal to the fair market value per share on the date of grant, as determined by the last closing price of the Company’s common stock the day prior to grant. As of December 31, 2019 the Company recorded $1,820,000 of compensation expenses for vested stock options. Beginning in October 2019, the board decided to increase CEO base salary to $35,000 per month. As of March 31, 2020 the Company recorded $287,500 of compensation expenses for common stock issued for services. On September 1, 2016, the Company entered into an amended and restated employment agreement with Mr. Lekhram Changoer, its Chief Technology Officer. The agreement does not have a set term and may be terminated at any time by the Company or Mr. Changoer with proper notice. Under the agreement Mr. Changoer receives an annual base compensation of $240,000 and an incentive payment of 2,000,000 shares of the Company’s common stock due upon execution of the agreement. On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary. The agreement does not have a set term and may be terminated at any time by the Company or Mr. Malasek with proper notice. The shares were issued in the 1 st On August 21, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into an agreement with Revive Therapeutics Ltd. (“Revive”) to begin selling the Company’s flagship nutraceutical product throughout the rapidly expanding Canadian cannabis market. The agreement defines a relationship where Revive will seek regulatory approval for AXIM’s proprietary, controlled-release functional chewing gum which contains hemp oil and cannabidiol (CBD). Under the terms of the agreement, Revive will have a minimum purchase amount annually, which increases each year for the term of the agreement. On September 10, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into a Letter of Intent (“LOI”) with Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, for exclusive distribution of all AXIM® Biotech products throughout Australia and New Zealand. Pursuant to the LOI, both parties will endeavor to enter into a definitive agreement whereby the parties will co-develop new products, initially for pre-clinical and phase 1 trials (among other clinical trials), including an oral rinse liquid targeted for the treatment of oral mucositis, strep throat, oral infections and gum disease. Pending initial discussions and an internal review of AXIM® Biotech and its product offerings, Impression will collaborate with AXIM® Biotech for the licensing and distribution of its current and future medicinal cannabis products for distribution in Australia and New Zealand. On December 20, 2018 the Company signed Exclusivity Agreement on terms that include Exclusivity period of 90 days after the date on which this agreement is executed with Impression in exchange for 10,300,000 ordinary fully paid shares in Impression at the price of A$0.02 per share and exchange rate of $0.74 AUD/USD valued $150,000 which the Company recognized as a revenue in 4 th On May 31, 2019, AXIM Biotechnologies, Inc. (“AXIM”) entered into a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, for the supply of the AXIM’s toothpaste and mouthwash containing cannabidiol (CBD) for its clinical trial for the treatment of periodontitis. The supply agreement is in preparation for a clinical trial to test the effectiveness of CBD in treating periodontitis. The clinical trial will be performed at Swinburne University of Technology in Melbourne, Australia. In accordance with the agreement, AXIM will supply the first batch of its patented toothpaste and mouthwash products containing CBD, along with associated placebo units for Impression to perform a randomized control clinical trial. On July 2, 2019, AXIM Biotechnologies, Inc. (“AXIM”) entered into a multi-term, non-exclusive license and distribution agreement (“Agreement”) with Colorado based gum developer, KISS Industries, LLC (“KISS Industries”). Under the terms of the Agreement, AXIM grants KISS Industries a non-exclusive license to formulate and sell products that fall within AXIM’s cannabinoid chewing gum patent in exchange for royalties to be paid to AXIM based upon KISS Industries sales in the United States and Mexico. The Agreement also grants AXIM the right to: (i) acquire 10 percent of KISS Industries under certain conditions; and (ii) match any outside future offer to acquire KISS Industries as a whole. Further, AXIM’s CEO John W. Huemoeller II will also join the Board of Directors of KISS Industries.. In exchange for this license Kiss Industries will pay Axim 6% of gross sales as a royalty on all licensed products sold by Kiss. In the territory covered by this license which is the USA and Mexico. (Minimum annual royalty $50,000). Kiss will manufacture for Axim various licensed products at a price equal to 140% of Kiss’s cost. As of December 31, 2019 and March 31, 2020 Kiss Industries did not sell any Axim’s products. Industry Sponsored Research Agreement— SAPPHIRE BIOTECH, Inc. entered into the Industry Sponsored Research Agreement (“SRA”) effective February 7, 2020 to test and confirm the inhibitory activity of SBI-183 (exclusively licensed on January 13, 2020) and SBI-183 analogs, including those synthesized by the Company. The testing will include cell-based in vitro assays, NMR binding studies and testing to determine if SBI-183 enhances the activity of cytotoxic drugs in vitro. Animal studies will also be conducted under the SRA. Specifically, SBI-183 analogs will be evaluated in a mouse model of triple negative breast cancer using human tumor xenografts. The work will be performed over a period of one year with the total cost of the SRA totaling $150,468 paid prior to acquisition. In consideration of the License executed between Skysong Innovations and the Company, the SRA provides for a reduced overhead of 5% instead of the usual 67.7%. This overhead fee differential of $89,851 will be deferred for five (5) years with interest of 5% compounded annually. Operating Lease The Company is renting an office at 45 Rockefeller Plaza 20 th The Company is renting a warehouse at Boelewerf 32, 2987 VD, Ridderkerk, Netherlands on a month to month basis, monthly rent is EUR 1,731 or approximately $2,000. Lease Agreement—On March 3, 2020, SAPPHIRE BIOTECH, Inc. entered into a 3-year lease agreement (“Lease”) to relocate to a larger space within the same business park. The current lease was due to expire September 30, 2020 and afforded 1,166 square feet at $2,595 base rent. The new space totals 1,908 square feet with base rent in the 1st year $4,713, 2nd year $4,854 and 3rd year $5,000. Upon commencement of the Lease on April 25, 2020, the previous lease will expire. Litigation As of March 31, 2020, and this report issuing date, the Company is not a party to any pending material legal proceeding. To the knowledge of management, no federal, state or local governmental agency is presently contemplating any proceeding against the Company. To the knowledge of management, no director, executive officer or affiliate of the Company, any owner of record or beneficially of more than five percent of the Company’s Common Stock is a party adverse to the Company or has a material interest adverse to the Company in any proceeding.

NOTE 18_ SUBSEQUENT EVENTS

NOTE 18: SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2020
Notes
NOTE 18: SUBSEQUENT EVENTS	NOTE 18: SUBSEQUENT EVENTS On April 1, 2020 the Company issued 1,953,125 S-3 shares valued at $250,000 pursuant to the Company’s Registration Statement on Form S-3. The cash was received subsequent to March 31, 2020. On April 21, 2020 the Company issued 2,000,000 S-3 shares valued at $298,000 pursuant to the Company’s Registration Statement on Form S-3. The cash was received subsequent to March 31, 2020. On April 21, 2020 the Company issued 1,176,470 restricted shares of its common stock to third party valued at $100,000 pursuant to the stock purchase agreement. The cash was received subsequent to March 31, 2020. On May 22, 2020 the Company issued 190,810 and 286,215 S-8 shares valued at $20,000 and $35,000 pursuant to the Company’s Registration Statement on Form S-8 for severance. On June 10, 2020 the Company issued 2,173,913 restricted shares of its common stock to third party valued at $500,000 pursuant to the stock purchase agreement. The cash was received subsequent to March 31, 2020. On June 24, 2020 the Company issued 625,000 restricted shares of its common stock to a third party valued at $100,000 pursuant to the stock purchase agreement. The cash was received subsequent to March 31, 2020. Impression Settlement Agreement On April 14, 2020 the company terminated its marketing and production agreement with impression healthcare by mutual consent of both parties. COVID-19 As previously discussed in the Current Report on Form 8-K filed by AXIM Biotechnologies, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on May 15, 2020, the filing of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2020 (the “Form 10-Q”) was delayed as a result of the disruptions caused by the novel coronavirus (“COVID-19”) pandemic, including the impact of (a) certain employees working from home, which slowed the Company’s routine quarterly close process, (b) delays in communications with various counterparts and (c) the need to perform additional analyses and procedures relating to the COVID-19 pandemic’s impact on the Company’s business and operations and on the financial statements included in the Form 10-Q. The Company has relied on the “Order Under Section 36 of the Securities Exchange Act Modifying Exemptions from the Reporting and Proxy Delivery Requirements for Public Companies” dated March 25, 2020 (Release No. 34-88465), issued by the SEC in light of the COVID-19 pandemic, to delay the filing of Form 10-Q; and expects to file its Quarterly report for the period ended March 31, 2020, on Form 10-Q approximately 45 days after May 15, 2020. Sanammad Settlement Agreement On May 6, 2020 (the “Effective Date”), AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”) by and among the Company, CanChew License Company (“CanCo”), CanChew Biotechnologies, LLC (“CanChew”), Medical Marijuana, Inc., Dr. George A. Anastassov (“Dr. Anastassov”), Dr. Philip A. Van Damme (“Dr. Van Damme”), Lekhram Changoer (“Mr. Changoer”), Sanammad Foundation, Netherlands and Sanammad Foundation, US (collectively, the “Sanammad Parties”), pursuant to which, among other matters as described herein, Drs. Anastassov and Van Damme and Mr. Changoer resigned as members of the Company’s Board of Directors. Pursuant to the Separation Agreement, the Company transferred and assigned to an entity designated by Dr. Anastassov all of the Company’s cannabis-related intellectual property other than the inventions and discoveries described in that certain cannabis-related patent application filed by the Company’s wholly-owned subsidiary, Sapphire Biotech, Inc. (water-soluble cannabinoid molecules). The Company also transferred 100% of its interest in CanCo and CanChew to an entity designated by Dr. Anastassov. In consideration for the transfers set forth above, any and all indebtedness owed by the Company to CanChew, totaling approximately $2.61 million, was satisfied and paid in its entirety. In addition, in consideration for the payment by the Company of $65,000, the Company purchased 100% of the issued and outstanding shares of Series B Preferred Stock held by the Sanammad Parties. Such shares shall be retired to treasury of the Company. The Sanammad Parties also agreed to forfeit and assign back to treasury, for no consideration, a total of 18,570,356 shares of the Company’s common stock. In addition, each of Drs. Anastassov and Van Damme and Mr. Changoer have agreed to subject the shares of the Company’s common stock held by each of them to lock-up and leak-out restrictions, as follows: they shall not sell shares for a period of 12 months following the Effective Date and, thereafter, subject to a daily volume limitation of 5%, on an aggregate basis among them. Further, the Company terminated the Consulting Agreement of Dr. Anastassov and the Employment Agreements for each of Dr. Van Damme and Mr. Changoer. In connection with the termination of Dr. Anastassov’s Consulting Agreement, the Company agreed to pay severance in the amount of $35,000 for March 2020 and $20,000 per month thereafter through July 2021 (the termination date contemplated by the Consulting Agreement). Commencing for the April 2020, the Company may, in its sole discretion, pay the $20,000 severance obligation by the issuance of shares of the Company’s common stock registered pursuant to the Registration Statement on Form S-8 filed with the Commission on May 29, 2015 (“S-8 Shares”). If the gross cash proceeds from the sale of any S-8 Shares issued in lieu of cash severance is less than $20,000, as determined 20 days after issuance of such S-8 Shares, then the Company has agreed to issue additional shares that would serve to “true-up” the value of the shares to the $20,000 monthly severance obligation; provided, however, that if 30 days after the date the severance payment is due the gross proceeds from the sale of S-8 Shares is less than $20,000, the Company must pay the shortfall in cash. In addition, for each month that Dr. Anastassov is entitled to receive severance, he shall receive S-8 Shares in an amount equal to the lesser of (a) 150,000 S-8 Shares, or (b) S-8 Shares valued at $15,000 based upon the closing price of the Company’s common stock as of the due date of the severance payment obligation. In connection with the termination of the Employment Agreements of Dr. Van Damme and Mr. Changoer, Mr. Changoer’s severance payments shall be $20,000 per month for 12 months, commencing April 2020 (paid in arrears) and Dr. Van Damme’s severance payments shall be $5,000 per month for 12 months, similarly commencing April 2020 and paid in arrears. The Company has the right to pay each of Dr. Van Damme’s and Mr. Changoer’s monthly severance payments in S-8 shares in lieu of cash subject to the same terms and restrictions (including true-up terms) as set forth above for Dr. Anastassov. The Company retains the right to prepay the severance obligations to Drs. Anastassov and Van Damme and Mr. Changoer, without penalty. No claims were alleged by the Company against any party, and no claims were alleged against the Company. However, in connection with the transactions described above, the parties entered into a general mutual release of all claims. Convertible Promissory Note As reported on the Company’s Current Report on Form 8-K dated December 7, 2018, on November 30, 2018, the Company issued to an institutional investor a Convertible Promissory Note (the “Note”), and the Note was later transferred to Medical Marijuana, Inc. (“Lender”). On May 6, 2020, the parties entered into an Addendum to the Note pursuant to which, commencing on May 1, 2020, interest shall accrue, at the original rate of 3.5%, and shall be payable on a semi-annual basis commencing November 1, 2020. The maturity date of the Note was extended until November 1, 2026. In addition, the Conversion Price was reduced in the Addendum from $1.50 to $0.25 per share. Purchase of Promissory Note and Forbearance Agreement Effective May 4, 2020, the Company acquired from TL-66, a California limited liability company (“Seller”), a promissory note issued to Seller by Dr. Anastassov (“Maker”) dated December 1, 2017, with a face value of $350,000 and a remaining balance due of approximately $100,000 (the “Note”). The purchase price for the Note was $100,000 payable by the Company issuing Seller One Million (1,000,000) restricted shares of the Company’s Common Stock. Effective May 6, 2020, the Company and Maker entered into a Forbearance Agreement whereby the Company agreed to forbear from making any collection efforts on the Note for a period of 24 months so long as Maker has not breached the Separation Agreement. Following 24 months, if there has been no breach of the Separation Agreement by Maker, repayment of the Note, including all principal and unpaid interest, will be waived in full.

NOTE 5_ SIGNIFICANT ACCOUNTIN_2

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Use of estimates (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Use of estimates	Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Significant estimates are assumptions about collection of accounts receivable, useful life of intangible assets and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate and expected dividend rate.

NOTE 5_ SIGNIFICANT ACCOUNTIN_3

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Cash equivalents (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Cash equivalents	Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. As of March 31, 2020 and December 31, 2019, the Company had no cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company had no uninsured balances at March 31, 2020 and December 31, 2019. The Company has never experienced any losses related to these balances.

NOTE 5_ SIGNIFICANT ACCOUNTIN_4

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Accounts Receivable (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Accounts Receivable	Accounts Receivable It is the Company’s policy to review accounts receivable at least on a monthly basis for conductibility and follow up with customers accordingly. Covid19 has slowed collection as our customers are in a mandated pause. We do not have geographic concentration of customers.

NOTE 5_ SIGNIFICANT ACCOUNTIN_5

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Concentrations (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Concentrations	Concentrations At March 31, 2020 and December 31, 2019, one customer and two customers accounted for 100% and 100% of accounts receivable, respectively. For the three months period ended March 31, 2020, one customer accounted for 24% of total revenue. For the three months period ended March 31, 2019, one customer accounted for 76% of total revenue.

NOTE 5_ SIGNIFICANT ACCOUNTIN_6

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Inventory	Inventory Inventory consists of finished goods available for sale and raw materials owned by the Company and are stated at the lower of cost or market. As of March 31, 2020 and December 31, 2019, the Company had $218,829 and $175,304 of finished goods and $291,472 and $312,511 of raw materials; respectively.

NOTE 5_ SIGNIFICANT ACCOUNTIN_7

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Property and equipment (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Property and equipment	Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. For the three months ended March 31, 2020 and 2019 the Company recorded $839 of depreciation expenses for each of these periods.

NOTE 5_ SIGNIFICANT ACCOUNTIN_8

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Intangible Assets (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Intangible Assets	Intangible Assets As required by generally accepted accounting principles, trademarks and patents are amortized if they have a definite life, and not amortized if they have an indefinite life and then they are tested annually for impairment. Intangible assets as of March 31, 2020 and December 31, 2019 amounted to $9,738,347 and $50,534 net of accumulated amortization and impairment losses of $668,535 and $664,898, respectively. During the three months period ended March 31, 2020 and 2019, the company recorded $3,637 and $3,158 of amortization and impairment loss, respectively.

NOTE 5_ SIGNIFICANT ACCOUNTIN_9

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Revenue Recognition	Revenue Recognition On January 1, 2018 the Company adopted guidance contained in Topic 606 (FASB ASC 606). The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods of services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. Revenues are recognized when title for goods is transferred; non-refundable fees and proceeds from irrevocable agreements recognized when inflows or other enhancements of assets of the Company are received. Revenues from operations recognized for three month ended March 31, 2020 and 2019 amounted to $7,140 and $17,061, respectively.

NOTE 5_ SIGNIFICANT ACCOUNTI_10

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc. Can Chew License Company, Marina Street LLC, Axim Biotechnologies (the Netherland Company) and Sapphire Biotech, Inc. and wholly-owned subsidiary Sapphire Diagnostics LLC as of March 31, 2020. All significant intercompany transactions and balances have been eliminated in consolidation.

NOTE 5_ SIGNIFICANT ACCOUNTI_11

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Derivative Liabilities (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of March 31, 2020 and December 31, 2019, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

NOTE 5_ SIGNIFICANT ACCOUNTI_12

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Fair Value Measurements	Fair Value Measurements The Company applies the guidance that is codified under ASC 820-10 related to assets and liabilities recognized or disclosed in the financial statements at fair value on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. The provisions of ASC 820-10 only apply to the Company’s investment securities, which are carried at fair value. ASC 820-10 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820-10 requires valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: Fair Value Hierarchy Inputs to Fair Value Methodology Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Quoted prices for similar assets or liabilities; quoted markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the financial instrument; inputs other than quoted prices that are observable for the asset or liability; or inputs that are derived principally from, or corroborated by, observable market information Level 3 Pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption is unobservable or when the estimation of fair value requires significant management judgment The Company categorizes a financial instrument in the fair value hierarchy based on the lowest level of input that is significant to its fair value measurement. As of March 31, 2020 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair ValueReported inFinancial Statements Marketable Securities $109,040 $ - $ - $109,040 As of December 31, 2019 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair Value Reported in Financial Statements Marketable Securities $213,745 $ - $ - $213,745 The Company recorded a change in FMV of trading securities as unrealized loss of $104,705 and unrealized gain of $25,000 for the three months ended March 31, 2020 and 2019, respectively. These securities are classified as trading. The Company did not have any Level 2 or Level 3 assets or liabilities as of March 31, 2020 and December 31, 2019, except for its convertible notes payable and derivative liability. The carrying amounts of these liabilities at March 31, 2020 and December 31, 2019 approximate their respective fair value based on the Company’s incremental borrowing rate. Cash is as of March 31, 2020 and December 31, 2019 is classified as Level 1 within our fair value hierarchy.

NOTE 5_ SIGNIFICANT ACCOUNTI_13

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Convertible Instruments (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”. Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instruments are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument”. The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

NOTE 5_ SIGNIFICANT ACCOUNTI_14

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Income Taxes	Income Taxes The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.

NOTE 5_ SIGNIFICANT ACCOUNTI_15

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Concentrations of Credit Risk (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. The Company had $240,769 and 0 allowance for doubtful accounts at March 31, 2020 and December 31, 2019. The Company had $175 accounts receivable at March 31, 2020 and $315,843 at December 31, 2019.

NOTE 5_ SIGNIFICANT ACCOUNTI_16

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Net Loss per Common Share (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Net Loss per Common Share	Net Loss per Common Share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. There were 22,367,172 common share equivalents at March 31, 2020 and 16,295,498 common shares at December 31, 2019. For the three months ended March 31, 2020 and 2019 these potential shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.

NOTE 5_ SIGNIFICANT ACCOUNTI_17

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Stock Based Compensation (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Stock Based Compensation	Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued.

NOTE 5_ SIGNIFICANT ACCOUNTI_18

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Cost of Sales (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Cost of Sales	Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs.

NOTE 5_ SIGNIFICANT ACCOUNTI_19

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Research and Development	Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $620,510 and $532,679 for the three months ended March 31, 2020 and 2019 respectively.

NOTE 5_ SIGNIFICANT ACCOUNTI_20

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Shipping Costs (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Shipping Costs	Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses.

NOTE 5_ SIGNIFICANT ACCOUNTI_21

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Recently Issued Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2020
Policies
Recently Issued Accounting Standards	Recently Issued Accounting Standards In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements The Company has a long-term operating lease, and the long-term operating lease only took effect in April 2020. Thus the adoption of ASC 842 had no impact on the condensed consolidated financial statements. In November 2018, the FASB issued ASU 2018-18 , Collaborative Arrangements (Topic 818): Clarifying the Interaction Between Topic 808 and Topic 606 In October 2018, the FASB issued ASU 2018-17, Targeted Improvements to Related Party Guidance for Variable Interest Entities In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 5_ SIGNIFICANT ACCOUNTI_22

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value Hierarchy for Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Fair Value Hierarchy for Financial Instruments	As of March 31, 2020 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair ValueReported inFinancial Statements Marketable Securities $109,040 $ - $ - $109,040 As of December 31, 2019 Quoted Market Prices in Active Markets(Level 1) Internal Models with Significant ObservableMarket Parameters(Level 2) Internal Modelswith Significant UnobservableMarket Parameters(Level 3) Total Fair Value Reported in Financial Statements Marketable Securities $213,745 $ - $ - $213,745

NOTE 6_ PREPAID EXPENSES_ Sched

NOTE 6: PREPAID EXPENSES: Schedule of Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Prepaid Expenses	March 31, 2020 December 31, 2019 Prepaid insurance $ 36,455 $ 67,734 Prepaid raw material/inventory 7,179 9,872 $ 43,634 $ 77,606

NOTE 9_ PROMISSORY NOTE - REL_2

NOTE 9: PROMISSORY NOTE - RELATED PARTY: Schedule of Promissory Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Promissory Notes Payable	March 31, 2020 December31, 2019 Promissory note payable, due on demand, interest at 3% p.a. $ 880,000 $ 880,000 Accrued Interest 173,436 166,926 $ 1,053,436 $ 1,046,926

NOTE 12_ CONVERTIBLE NOTES PA_2

NOTE 12: CONVERTIBLE NOTES PAYABLE: Schedule of Convertible Notes Payable, Shareholder (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Convertible Notes Payable, Shareholder	March 31, 2020 December 31, 2019 Convertible note payable, due on July 1, 2028, interest at 3.5% p.a. $ 45,000 $ 45,000 Accrued interest 5,972 5,578 $ 50,972 $ 50,578

NOTE 12_ CONVERTIBLE NOTES PA_3

NOTE 12: CONVERTIBLE NOTES PAYABLE: Schedule of Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Convertible Notes Payable	March 31, 2020 December 31, 2019 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. $ 484,478 $ 484,478 Convertible note payable, due on October 1, 2029, interest at 3.5% p.a. 1,000,000 1,000,000 Convertible note payable, due on November 1, 2021, interest at 3.5% p.a. 4,000,000 4,000,000 Convertible note payable, due on December 31, 2034, interest at 3% p.a. 190,000 - Accrued interest 235,897 261,541 Total 5,910,375 5,746,019 Less: unamortized debt discount/finance premium costs (910,370) (739,732) Convertible note payable, net 5,000,005 5,006,287 Less: current portion - - Long term portion $ 5,000,005 $ 5,006,287

NOTE 15_ STOCK OPTIONS_ Schedul

NOTE 15: STOCK OPTIONS: Schedule of options under Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of options under Stock Option Plan	Options Outstanding Options Exercisable Exercise Prices ($) Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price ($) Number Exercisable Weighted Average Exercise Price ($) $0.75 2,000,000 9 $0.75 2,000,000 $0.75

NOTE 15_ STOCK OPTIONS_ Sched_2

NOTE 15: STOCK OPTIONS: Schedule of Stock Option Activity (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Stock Option Activity	Options Outstanding Weighted Average Exercise Price Outstanding at December 31, 2019 2,000,000 $0.75 Granted - - Exercised - - Expired or canceled - - Outstanding at March 31, 2020 2,000,000 $ 0.75

NOTE 16_ BUSINESS COMBINATION_2

NOTE 16: BUSINESS COMBINATION - SAPPHIRE: Schedule of Consideration Paid for Sapphire Biotech (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Consideration Paid for Sapphire Biotech	Consideration: Cash and cash equivalents $ 79,814 Property and equipment, net 20,533 Intangible assets including goodwill 9,763,233 Security deposit 12,785 Total asset acquired $ 9,876,365 Accrued expenses and other current liabilities $ 5,767 Deferred taxes liability 1,845,000 Notes Payable including convertible and discount on conversion 519,598 Total liabilities assumed $ 2,370,365 Net assets acquired $ 7,506,000

NOTE 16_ BUSINESS COMBINATION_3

NOTE 16: BUSINESS COMBINATION - SAPPHIRE: Schedule of Consolidated Results of Operations related to Acquisition of Sapphire Biotech (Tables)	3 Months Ended
	Mar. 31, 2020
Tables/Schedules
Schedule of Consolidated Results of Operations related to Acquisition of Sapphire Biotech	March 31, 2020 March 31, 2019 Revenues $ $7,140 $ $17,061 Net income(loss) $ (2,455,268) $ (2,403,488) Net loss per share—Basic $ (0.02) $ (0.02) Net loss per share—Diluted $ (0.02) $ (0.02)

NOTE 1_ ORGANIZATION (Details)

NOTE 1: ORGANIZATION (Details)	3 Months Ended
	Mar. 31, 2020
Details
Entity Incorporation, State or Country Code	NV
Entity Incorporation, Date of Incorporation	Nov. 18, 2010
Entity Information, Former Legal or Registered Name	Axim International Inc.
Entity Information, Date to Change Former Legal or Registered Name	Jul. 24, 2014

NOTE 4_ GOING CONCERN (Details)

NOTE 4: GOING CONCERN (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Details
Working Capital	$ (3,242,140)
Accumulated deficit	(37,468,409)		$ (35,440,042)
Net cash used in operating activities	$ (1,111,195)	$ (728,549)

NOTE 5_ SIGNIFICANT ACCOUNTI_23

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Inventory (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Details
Finished goods inventory	$ 218,829	$ 175,304
Raw materials inventory	$ 291,472	$ 312,511

NOTE 5_ SIGNIFICANT ACCOUNTI_24

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Property and equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Depreciation, Amortization and Accretion, Net	$ 839	$ 839

NOTE 5_ SIGNIFICANT ACCOUNTI_25

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Intangible Assets (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Details
Intangible Assets, Net (Excluding Goodwill)	$ 9,738,347	$ 50,534
Impairment of Intangible Assets (Excluding Goodwill)	$ 668,535	$ 664,898

NOTE 5_ SIGNIFICANT ACCOUNTI_26

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Revenue, Continuing Operations	$ 7,140	$ 17,061

NOTE 5_ SIGNIFICANT ACCOUNTI_27

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Fair Value Measurements: Schedule of Fair Value Hierarchy for Financial Instruments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Inputs, Level 1
Marketable Securities	$ 109,040	$ 213,745
Fair Value, Inputs, Level 2
Marketable Securities	0	0
Fair Value, Inputs, Level 3
Marketable Securities	0	0
Fair Value, Inputs, Level 1, 2 and 3
Marketable Securities	$ 109,040	$ 213,745

NOTE 5_ SIGNIFICANT ACCOUNTI_28

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Net Loss per Common Share (Details) - shares	Mar. 31, 2020	Dec. 31, 2019
Details
Common Share Equivalents	22,367,172	16,295,498

NOTE 5_ SIGNIFICANT ACCOUNTI_29

NOTE 5: SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Research and development expenses	$ 620,510	$ 532,679

NOTE 6_ PREPAID EXPENSES_ Sch_2

NOTE 6: PREPAID EXPENSES: Schedule of Prepaid Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Prepaid expenses	$ 43,634	$ 77,606
Prepaid insurance
Prepaid expenses	36,455	67,734
Prepaid raw material/inventory
Prepaid expenses	$ 7,179	$ 9,872

NOTE 6_ PREPAID EXPENSES (Detai

NOTE 6: PREPAID EXPENSES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Amortization of Prepaid Expenses	$ 31,280	$ 25,768

NOTE 7_ MARKETABLE SECURITIES (

NOTE 7: MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Details
Marketable Securities, Realized Gain (Loss)	$ 0	$ 0
Marketable Securities, Unrealized Gain (Loss)	$ (104,705)	$ 25,000

NOTE 8_ INVESTMENT IN THIRD P_2

NOTE 8: INVESTMENT IN THIRD PARTY (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Details
Investment in Joint Venture	$ 27,490	$ 27,490

NOTE 9_ PROMISSORY NOTE - REL_3

NOTE 9: PROMISSORY NOTE - RELATED PARTY: Schedule of Promissory Notes Payable (Details) - Promissory note - related party - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Debt Instrument, Description			Promissory note payable, due on demand, interest at 3% p.a.
Debt Instrument, Face Amount	$ 880,000	$ 880,000	$ 880,000
Accrued Interest	173,436	166,926
Long-term Debt	$ 1,053,436	$ 1,046,926	$ 1,053,436

NOTE 9_ PROMISSORY NOTE - REL_4

NOTE 9: PROMISSORY NOTE - RELATED PARTY (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Promissory note - related party
Interest Expense, Promissory Note	$ 6,510	$ 6,510

NOTE 10_ RELATED PARTY TRANSA_2

NOTE 10: RELATED PARTY TRANSACTIONS (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Details
Due to related party	$ 1,526,603	$ 1,526,603
Loan receivable	$ 5,000	$ 5,000

NOTE 11_ DUE TO FIRST INSURAN_2

NOTE 11: DUE TO FIRST INSURANCE FUNDING (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Due to first insurance funding	$ 7,782	$ 42,121
Due to First Insurance Funding #1
Related Party Transaction, Description of Transaction	Company renewed its D&O and EPLI insurance policy
Due to First Insurance Funding #2
Related Party Transaction, Description of Transaction	Company renewed its CL Products Liability insurance policy

NOTE 12_ CONVERTIBLE NOTES PA_4

NOTE 12: CONVERTIBLE NOTES PAYABLE: Schedule of Convertible Notes Payable, Shareholder (Details) - Convertible notes payable due to shareholder - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument, Description	Convertible note payable, due on July 1, 2028, interest at 3.5% p.a.
Debt Instrument, Maturity Date	Jul. 1, 2028
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Debt Instrument, Face Amount	$ 45,000	$ 45,000
Interest Payable, Current	5,972	5,578
Long-term Debt	$ 50,972	$ 50,578

NOTE 12_ CONVERTIBLE NOTES PA_5

NOTE 12: CONVERTIBLE NOTES PAYABLE: Schedule of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Total	$ 5,910,375	$ 5,746,019	$ 5,910,375
Less unamortized debt discount	(910,370)	(739,732)	(910,370)
Convertible note payable, net	5,000,005	5,006,287
Less current portion	0	0	0
Long term portion	$ 5,000,005	5,006,287	$ 5,000,005
Convertible Note 1
Debt Instrument, Description			Convertible note payable, due on October 1, 2029, interest at 3.5% p.a.
Debt Instrument, Maturity Date			Oct. 1, 2029
Debt Instrument, Interest Rate, Stated Percentage	3.50%		3.50%
Debt Instrument, Face Amount	$ 484,478	484,478	$ 484,478
Convertible Note 2
Debt Instrument, Description			Convertible note payable, due on October 1, 2029, interest at 3.5% p.a.
Debt Instrument, Maturity Date			Oct. 1, 2029
Debt Instrument, Interest Rate, Stated Percentage	3.50%		3.50%
Debt Instrument, Face Amount	$ 1,000,000	1,000,000	$ 1,000,000
Convertible Note 3
Debt Instrument, Description			Convertible note payable, due on November 1, 2021, interest at 3.5% p.a.
Debt Instrument, Maturity Date			Nov. 1, 2021
Debt Instrument, Interest Rate, Stated Percentage	3.50%		3.50%
Debt Instrument, Face Amount	$ 4,000,000	4,000,000	$ 4,000,000
Convertible Note 4
Debt Instrument, Description			Convertible note payable, due on December 31, 2034, interest at 3% p.a.
Debt Instrument, Maturity Date			Dec. 31, 2034
Debt Instrument, Interest Rate, Stated Percentage	3.00%		3.00%
Debt Instrument, Face Amount	$ 190,000	0	$ 190,000
Convertible Notes
Accrued interest	$ 235,897	$ 261,541	$ 235,897

NOTE 12_ CONVERTIBLE NOTES PA_6

NOTE 12: CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Details
Secured convertible notes	$ 4,053,259		$ 4,093,333
Secured convertible notes, accrued interest	53,259		$ 93,333
Investment Income, Net, Amortization of Discount and Premium	$ (19,363)	$ (18,662)

NOTE 13_ STOCK INCENTIVE PLAN (

NOTE 13: STOCK INCENTIVE PLAN (Details)	Mar. 31, 2020shares
Details
Stock Incentive Plan, Shares Available for Issuance	9,806,000

NOTE 14_ STOCKHOLDERS' DEFICIT_

NOTE 14: STOCKHOLDERS' DEFICIT: Preferred Stock (Details) - Preferred Stock - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001

NOTE 14_ STOCKHOLDERS' DEFICI_2

NOTE 14: STOCKHOLDERS' DEFICIT: Series A Convertible Preferred Stock (Details)	Mar. 31, 2020shares
Details
Shares authorized, Series A Convertible Preferred Stock	1,000,000

NOTE 14_ STOCKHOLDERS' DEFICI_3

NOTE 14: STOCKHOLDERS' DEFICIT: Series B Convertible Preferred Stock (Details)	Aug. 18, 2016shares
Details
Shares issued, Series B Preferred Stock	500,000

NOTE 14_ STOCKHOLDERS' DEFICIT

NOTE 14: STOCKHOLDERS' DEFICIT (Details) - shares	Mar. 31, 2020	Dec. 31, 2019	Aug. 18, 2016
Shares issued, Series C Preferred Stock			500,000
Series C Convertible Preferred Stock
Preferred Stock, Shares Authorized	500,000	500,000

NOTE 14_ STOCKHOLDERS' DEFICI_4

NOTE 14: STOCKHOLDERS' DEFICIT: Common Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	123,309,045	64,854,539
Sale of Stock, Transaction Date	May 22, 2020
Stock Issuance #1
Stock Issued During Period, Shares, New Issues	3,541,667
Stock Issued	$ 962,500
Stock Issuance #2
Stock Issued During Period, Shares, New Issues	250,000
Stock Issued	$ 50,000
Sale of Stock, Transaction Date	Jan. 13, 2020
Stock Issuance #3
Stock Issued During Period, Shares, New Issues	600,000
Stock Issued	$ 262,500
Sale of Stock, Transaction Date	Jan. 23, 2020
Stock Issuance #4
Stock Issued During Period, Shares, New Issues	62,839
Stock Issued	$ 25,000
Sale of Stock, Transaction Date	Feb. 26, 2020
Stock Issuance #5
Stock Issued During Period, Shares, New Issues	1,250,000
Stock Issued	$ 1,592,813
Stock Issuance #6
Stock Issued During Period, Shares, New Issues	239,521
Stock Issued	$ 400,000
Sale of Stock, Transaction Date	Mar. 12, 2019

NOTE 15_ STOCK OPTIONS_ Sched_3

NOTE 15: STOCK OPTIONS: Schedule of Stock Option Activity (Details) - Option activity	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | shares	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares	$ 0
Number Outstanding | shares	2,000,000
Weighted Average Exercise Price ($) | $ / shares	$ 0.75

NOTE 16_ BUSINESS COMBINATION_4

NOTE 16: BUSINESS COMBINATION - SAPPHIRE: Schedule of Consideration Paid for Sapphire Biotech (Details)	Mar. 31, 2020USD ($)
Details
Acquisition of Sapphire Biotech - Cash and cash equivalents	$ 79,814
Acquisition of Sapphire Biotech - Property and equipment, net	20,533
Acquisition of Sapphire Biotech - Intangible assets including goodwill	9,763,233
Acquisition of Sapphire Biotech - Security deposit	12,785
Acquisition of Sapphire Biotech - Total asset acquired	9,876,365
Acquisition of Sapphire Biotech - Accrued expenses and other current liabilities	5,767
Acquisition of Sapphire Biotech - Deferred taxes liability	1,845,000
Acquisition of Sapphire Biotech - Notes Payable including convertible and discount on conversion	519,598
Acquisition of Sapphire Biotech - Total liabilities assumed	2,370,365
Acquisition of Sapphire Biotech - Net assets acquired	$ 7,506,000

NOTE 16_ BUSINESS COMBINATION_5

NOTE 16: BUSINESS COMBINATION - SAPPHIRE: Schedule of Consolidated Results of Operations related to Acquisition of Sapphire Biotech (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Details
Acquisition of Sapphire Biotech - Revenues	$ 7,140	$ 17,061
Acquisition of Sapphire Biotech - Net income(loss)	$ (2,455,268)	$ (2,403,488)
Acquisition of Sapphire Biotech - Net loss per share-Basic	$ (0.02)	$ (0.02)
Acquisition of Sapphire Biotech - Net loss per share-Diluted	$ (0.02)	$ (0.02)

NOTE 17_ COMMITMENT AND CONTI_2

NOTE 17: COMMITMENT AND CONTINGENCIES (Details)	3 Months Ended
	Mar. 31, 2020
Commitment 1
Other Commitments, Description	On September 1, 2016, the Company entered into an amended and restated employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary
Commitment 2
Other Commitments, Description	On September 1, 2016, the Company entered into an amended and restated employment agreement with Mr. Lekhram Changoer, its Chief Technology Officer
Commitment 3
Other Commitments, Description	On April 24, 2017 the company entered into an employment agreement with Robert Malasek, its Chief Financial Officer and Secretary
Commitment 4
Other Commitments, Description	On August 21, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into an agreement with Revive Therapeutics Ltd. (“Revive”) to begin selling the Company’s flagship nutraceutical product
Commitment 5
Other Commitments, Description	On September 10, 2018, AXIM Biotechnologies, Inc. (the “Company”) entered into a Letter of Intent (“LOI”) with Impression Healthcare Limited (“Impression”), Australia’s largest home dental impression company, for exclusive distribution of all AXIM® Biotech products
Commitment 6
Other Commitments, Description	On May 31, 2019, AXIM Biotechnologies, Inc. (“AXIM”) entered into a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”)
Commitment 7
Other Commitments, Description	On July 2, 2019, AXIM Biotechnologies, Inc. (“AXIM”) entered into a multi-term, non-exclusive license and distribution agreement (“Agreement”) with Colorado based gum developer, KISS Industries, LLC
Commitment 8
Other Commitments, Description	The Company is renting an office
Commitment 9
Other Commitments, Description	The Company is renting a warehouse
Commitment 10
Other Commitments, Description	On March 3, 2020, SAPPHIRE BIOTECH, Inc. entered into a 3-year lease agreement (“Lease”) to relocate to a larger space

NOTE 18_ SUBSEQUENT EVENTS (Det

NOTE 18: SUBSEQUENT EVENTS (Details)	3 Months Ended
	Mar. 31, 2020USD ($)shares
Sale of Stock, Transaction Date	May 22, 2020
Event 1
Subsequent Event, Date	Apr. 1, 2020
Sale of Stock, Transaction Date	Apr. 1, 2020
Subsequent Event, Description	Company issued 1,953,125 S-3 shares
Stock Issued During Period, Shares, New Issues | shares	1,953,125
Stock Issued | $	$ 250,000
Event 2
Subsequent Event, Date	Apr. 21, 2020
Sale of Stock, Transaction Date	Apr. 21, 2020
Subsequent Event, Description	Company issued 2,000,000 S-3 shares
Stock Issued During Period, Shares, New Issues | shares	2,000,000
Stock Issued | $	$ 298,000
Event 3
Subsequent Event, Date	Apr. 21, 2020
Sale of Stock, Transaction Date	Apr. 21, 2020
Subsequent Event, Description	Company issued 1,176,470 restricted shares of its common stock
Stock Issued During Period, Shares, New Issues | shares	1,176,470
Stock Issued | $	$ 100,000
Event 4
Subsequent Event, Date	May 22, 2020
Sale of Stock, Transaction Date	May 22, 2020
Stock Issued During Period, Shares, New Issues | shares	190,810
Stock Issued | $	$ 20,000
Event 5
Subsequent Event, Date	May 22, 2020
Stock Issued During Period, Shares, New Issues | shares	286,215
Stock Issued | $	$ 35,000
Event 6
Subsequent Event, Date	Jun. 10, 2020
Sale of Stock, Transaction Date	Jun. 10, 2020
Subsequent Event, Description	Company issued 2,173,913 restricted shares of its common stock
Stock Issued During Period, Shares, New Issues | shares	2,173,913
Stock Issued | $	$ 500,000
Event 7
Sale of Stock, Transaction Date	Jun. 24, 2020
Subsequent Event, Description	Company issued 625,000 restricted shares of its common stock
Stock Issued During Period, Shares, New Issues | shares	625,000
Stock Issued | $	$ 100,000
Event 8
Subsequent Event, Date	Apr. 14, 2020
Subsequent Event, Description	company terminated its marketing and production agreement with impression healthcare
Event 9
Subsequent Event, Date	May 6, 2020
Subsequent Event, Description	AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), entered into an Agreement (the “Separation Agreement”)
Event 10
Subsequent Event, Description	Company terminated the Consulting Agreement of Dr. Anastassov and the Employment Agreements for each of Dr. Van Damme and Mr. Changoer
Event 11
Subsequent Event, Date	May 6, 2020
Subsequent Event, Description	parties entered into an Addendum to the Note
Event 12
Subsequent Event, Date	May 4, 2020
Subsequent Event, Description	Company acquired from TL-66, a California limited liability company (“Seller”), a promissory note issued to Seller by Dr. Anastassov (“Maker”)